News
The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...
The U.S. Centers for Disease Control and Prevention has accepted recommendations made by a panel of vaccine experts in April, ...
11d
Zacks Investment Research on MSNMRNA Stock Jumps on CDC's Revised RSV Vaccine RecommendationsShares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...
The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...
12d
MedPage Today on MSNCDC Follows Advice of Ousted Vaccine Panel, Expands Access to RSV ShotWith the CDC director's chair still empty, HHS Secretary Robert F. Kennedy Jr. endorsed recommendations made months ago by ...
The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...
1h
Zacks Investment Research on MSNFDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger AdultsGSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...
The U.S. Centers for Disease Control and Prevention (CDC) has accepted recommendations from an advisory panel that endorsed ...
The U.S. Centers for Disease Control and Prevention has accepted recommendations made by an advisory panel in April on the use of respiratory syncytial virus vaccines in adults aged between 50 and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results